Twist Bioscience Corp
TWST
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.95B
Close$
$10.13
92.4% downside
Current Fair Value
92.4% downsideOvervalued by 92.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.95 Billion |
|---|---|
| Enterprise Value | $9.93 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.3 |
| Beta | 2.19 |
| Outstanding Shares | 62,403,000 |
Return
| Return on Equity | -30.67% |
|---|---|
| Return on Assets | -20.33% |
| Return on Invested Capital | -25.50% |
Valuation & Multiples
| P/E Ratio | -71.97 |
|---|---|
| PEG | 26.47 |
| Price to Sales | 22.13 |
| Price to Book Ratio | 18.96 |
| Enterprise Value to Revenue | 23 |
| Enterprise Value to EBIT | -70.55 |
| Enterprise Value to Net Income | -73 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$114.55 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$123.59 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 39.14% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.04%▼ 124.70% |
|---|---|
| Total Invested | $4.46M▼ 99.94% |
| Investors Holding | 7▼ 341.00% |
ESG Score
No data
About Twist Bioscience Corp
CEO: Emily Leproust Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary techno...